February 5, 2025

The Honorable Mike Johnson Speaker of the House United States House of Representatives Washington, DC 20510

The Honorable John Thune Majority Leader United States Senate Washington, DC 20510 The Honorable Hakeem Jeffries Minority Leader United States House of Representatives Washington, DC 20510

The Honorable Chuck Schumer Minority Leader United States Senate Washington, DC 20510

Dear Speaker Johnson, Leader Jeffries, Leader Thune and Leader Schumer:

We, the undersigned organizations, urge you to include the bipartisan pharmacy benefit manager (PBM) reforms that were agreed upon in the context of the December continuing resolution in any package that may materialize to extend government spending past March 15. These reforms have received overwhelming bipartisan support both inside the halls of Congress and among the American public and would have an immediate impact on the lives of millions of Americans who have, for too long, been paying more than they should for prescription drugs.

It is time for Congress to take action. Multiple bills were advanced by several Senate and House committees last Congress, all supporting the underlying goal – to address anti-competitive, anti-consumer practices employed by PBMs. By enacting these measures, you can deliver relief to patients and families at their local pharmacies, employers facing continued increases in healthcare costs, and taxpayers who are currently overpaying for government-provided benefit programs.

The important policy work on reaching bipartisan agreement on these reforms has already been accomplished by leadership as evidenced by the healthcare package that was expected to be included in the December continuing resolution. This agreement includes policies that were approved by committees of jurisdiction to de-link drug prices from PBM revenues, share negotiated savings with employers, workers and their families, ban spread pricing, and require transparency from the PBM corporations that have persistently resisted it.

These reforms have broad public and political support. They passed House and Senate committees with little opposition. President Trump has spoken frequently of the need to address PBM abuses. And the American public is tired of paying too much out of pocket for the medicines they need.

We urge you to include these reforms in legislation to extend government funding beyond March 15 that may be under consideration. This is an immediate opportunity to deliver tangible gains to American taxpayers and voters. Thank you for your leadership.

Sincerely,

America's Agenda Blue Shield of California The ERISA Industry Committee National Association of Chain Drug Stores National Community Pharmacists Association PBM Accountability Project Transparency-Rx